Chemed (CHE) Beat Expectations, Is The Stock Already Fully Valued?

Simply Wall St.06-26

AdvertisementChemed’s earnings beat puts fresh attention on the stock Chemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646893382?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-06-26 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646893382","market":"hk","top_or_hot":-1,"title":"Chemed (CHE) Beat Expectations, Is The Stock Already Fully Valued?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementChemed’s earnings beat puts fresh attention on the stock Chemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-che/chemed/news/chemed-che-beat-expectations-is-the-stock-already-fully-valu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemed (CHE) Beat Expectations, Is The Stock Already Fully Valued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemed (CHE) Beat Expectations, Is The Stock Already Fully Valued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-26 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-che/chemed/news/chemed-che-beat-expectations-is-the-stock-already-fully-valu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementChemed’s earnings beat puts fresh attention on the stock Chemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-che/chemed/news/chemed-che-beat-expectations-is-the-stock-already-fully-valu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHE","symbol_name":"Chemed Corp","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-che/chemed/news/chemed-che-beat-expectations-is-the-stock-already-fully-valu","article_id":"2646893382","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-che/chemed/news/chemed-che-beat-expectations-is-the-stock-already-fully-valu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646893382","pubTimestamp":1782429903,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Chemed’s earnings beat puts fresh attention on the stock\nChemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat exceeded analysts’ expectations and coincided with the stock moving higher.\nSee our latest analysis for Chemed.\nChemed’s recent earnings beat has coincided with a strong 90 day share price return of 22.94%. However, the 1 year total shareholder return is still down 18.04%, so recent momentum contrasts with a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHE":"Chemed Corp","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","LU2413665964.HKD":"BNP PARIBAS AQUA \"C\" (HKD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU1721427968.SGD":"BNP PARIBAS AQUA \"CRH\" (SGDHDG) INC","LU1543694498.USD":"法巴水资源基金RH MD Dis","LU2413666004.HKD":"BNP PARIBAS AQUA \"CRH\" (HKDHDG) INC","BK4185":"保健护理机构","CON":"Concentra Group Holdings Parent Inc","LU1620156213.USD":"BNP PARIBAS AQUA \"C\" (USD) INC","LU1596574779.USD":"BNP PARIBAS AQUA \"C\" (USDHDG) ACC","BK4196":"保健护理服务","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1620156130.USD":"BNP PARIBAS AQUA \"C\" (USD) ACC"},"translate_title":"Chemed(CHE)超出预期，该股是否已完全估值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CON":1,"CHE":1.5},"content_text":"AdvertisementChemed’s earnings beat puts fresh attention on the stock Chemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat exceeded analysts’ expectations and coincided with the stock moving higher. See our latest analysis for Chemed. Chemed’s recent earnings beat has coincided with a strong 90 day share price return of 22.94%. However, the 1 year total shareholder return is still down 18.04%, so recent momentum contrasts with a weaker longer term picture. If this earnings driven move has you reassessing opportunities in healthcare, it can be useful to see what else is moving and compare Chemed with 39 healthcare AI stocks With Chemed trading at $453.15, close to analysts’ $446.50 price target yet showing an intrinsic discount estimate of 33.63%, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 1.5% Overvalued Chemed’s most followed narrative pegs fair value at $446.50 using a 7.11% discount rate, slightly below the latest close at $453.15. This frames a tight valuation gap. The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (for example, Pinellas and Marion) is expected to materially expand VITAS's service footprint. This aligns with the continued aging U.S. population and the shift toward home-based care, both cited as key drivers of higher patient volumes and long-term top-line revenue growth. Read the complete narrative. This raises the question of what earnings path and margin profile would need to hold for Chemed to justify that fair value, and how buybacks may affect the share count. Result: Fair Value of $446.50 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Chemed’s story also carries real pressure points, including reimbursement caps at VITAS, as well as weaker residential demand and higher insurance and labor costs at Roto-Rooter. Find out about the key risks to this Chemed narrative. Another View: Chemed’s valuation through the fair P/E lens The DCF based narrative sees Chemed as about 1.5% overvalued around $446.50 per share, yet on P/E the picture looks different. Chemed trades at 23.1x earnings, close to its fair ratio of 23.2x and far below the 104.4x peer average. This points to limited multiple risk but also a tighter margin of safety. Which signal do you weigh more heavily? For investors who prefer simple ratios over cash flow models, this P/E view offers a straightforward cross check on the story. The fair ratio also gives a sense of where the market could gravitate if sentiment normalizes. It still leaves the question of how comfortable you are with paying close to that implied benchmark for Chemed’s earnings power. See what the numbers say about this price — find out in our valuation breakdown. NYSE:CHE P/E Ratio as at Jun 2026Next Steps With Chemed’s mixed signals on valuation and recent price action, how does the balance of concern and optimism sit with you right now? Take a moment to weigh both sides of the story, then use the 3 key rewards and 1 important warning sign Looking for more investment ideas beyond Chemed? If Chemed has sharpened your focus, do not stop here; widen your opportunity set with a few targeted stock ideas built from clear, data driven filters.  Target stability first by checking companies screened for resilience in tougher conditions through the 67 resilient stocks with low risk scores Hunt for potential bargains by scanning quality businesses with room for upside using the 43 high quality undervalued stocks Spot resilient earners with healthy financial foundations by reviewing the solid balance sheet and fundamentals stocks screener (48 results)   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646893382","isCrawlerRequest":true}